ARA-290: Dosage, Benefits & Research Guide
What is ARA-290?
ARA-290, also known as cibinetide, is a small peptide derived from the structure of erythropoietin that selectively engages the innate repair receptor (a heteromer of the EPO receptor and the CD131 beta-common receptor) without stimulating erythropoiesis. Research has explored its role in modulating inflammatory cascades, supporting neuronal and vascular tissue under stress, and influencing pain pathways associated with small-fiber neuropathy. Because it does not raise hematocrit, it has been investigated as a tool for studying tissue-protective EPO signaling in isolation. This compound is supplied as a lyophilized powder for in-vitro and laboratory research use only and is not intended for human or veterinary use.
ARA-290 Research Applications
In published and preclinical research, ARA-290 has been studied across the following areas:
- Innate repair receptor signaling research
- Anti-inflammatory pathway studies
- Neuroprotection and small-fiber neuropathy models
- Tissue repair research
ARA-290 in Research: Reconstitution & Study Concentrations
ARA-290 is supplied as a lyophilized powder. For laboratory research it is reconstituted with bacteriostatic or sterile water; the solvent volume sets the working concentration. Published studies select concentrations specific to the assay or model system — there is no human dose, as ARA-290 is not approved for human use. Researchers should reference the primary literature for the model in question and document the exact lot COA.
Worked example: a 10mg vial reconstituted with 2 mL of bacteriostatic water yields 5.00 mg/mL.
Open the reconstitution calculator